Golub L M, Lee H M, Greenwald R A, Ryan M E, Sorsa T, Salo T, Giannobile W V
Department of Oral Biology and Pathology, School of Dental Medicine, State University of New York, Stony Brook 11794, USA.
Inflamm Res. 1997 Aug;46(8):310-9. doi: 10.1007/s000110050193.
To determine whether an inhibitor of matrix metalloproteinases (MMPs), administered to human subjects in a dental school research clinic, can reduce bone-type collagen degradation fragments in oral inflammatory exudates containing excessive levels of collagenase.
Gingival crevicular fluid (GCF) was collected from 18 subjects with adult periodontitis whose clinical findings (gingival inflammation, pocket depth, and bone loss on radiographs) predicted excessive MMP activity in their periodontal pockets.
One month before the baseline appointment, plaque and calculus were removed from the teeth by supra- and subgingival scaling. After collection of GCF from 8-12 pocket sites per subject and recording of clinical indices, 12 of the 18 subjects were treated with doxycycline at a low dosage (20 mg b.i.d.) known via an extensive literature to suppress mammalian MMP activity by a non-antimicrobial mechanism. The remaining 6 subjects were followed without drug treatment.
At the baseline, 1 and 2-month appointments, GCF samples were analyzed for ICTP. (carboxyterminal peptide, a pyridinoline-containing fragment of Type I collagen) and osteocalcin by radioimmunoassay, as well as collagenolytic enzyme activity and MMP species (Western blot). Statistical analyses were determined by ANOVA.
GCF ICTP and functional collagenase activity (but not osteocalcin levels) were significantly reduced (p < 0.05) in the doxycycline-treated subjects at both 1 and 2 month evaluations: there was no such change in the non-treated subjects. Western blots revealed that neutrophil-type collagenase (MMP-8) was the predominant MMP; MMP-13, which has been associated with pathologic collagenolysis including bone resorption, was detected in human GCF for the first time and was more substantially reduced than MMP-8.
This is the first demonstration in human subjects of the simultaneous reduction of excessive MMP activity with concomitant reduction in levels of collagen degradation fragments. The findings are potentially applicable to a wide variety of human diseases characterized by excessive collagenase activity.
为了确定在牙科学校研究诊所给予人类受试者的基质金属蛋白酶(MMPs)抑制剂是否能减少含有过量胶原酶的口腔炎性渗出物中骨型胶原降解片段。
从18名成人牙周炎患者中收集龈沟液(GCF),这些患者的临床检查结果(牙龈炎症、牙周袋深度和X线片上的骨质流失)预示其牙周袋中MMP活性过高。
在基线检查前一个月,通过龈上和龈下刮治术清除牙齿上的菌斑和牙石。在从每位受试者的8 - 12个牙周袋部位收集GCF并记录临床指标后,18名受试者中的12名接受低剂量强力霉素(20mg,每日两次)治疗,大量文献表明该剂量可通过非抗菌机制抑制哺乳动物MMP活性。其余6名受试者不接受药物治疗,进行随访。
在基线、第1个月和第2个月检查时,对GCF样本进行分析,通过放射免疫测定法检测ICTP(羧基末端肽,I型胶原的含吡啶啉片段)和骨钙素,同时检测胶原酶活性和MMP种类(蛋白质印迹法)。采用方差分析进行统计学分析。
在第1个月和第2个月评估时,强力霉素治疗组受试者的GCF ICTP和功能性胶原酶活性(但骨钙素水平未降低)显著降低(p < 0.05);未治疗组受试者无此变化。蛋白质印迹显示中性粒细胞型胶原酶(MMP - 8)是主要的MMP;首次在人类GCF中检测到与包括骨吸收在内的病理性胶原溶解相关的MMP - 13,且其降低幅度比MMP - 8更大。
这是首次在人类受试者中证明同时降低过量的MMP活性并伴随胶原降解片段水平的降低。这些发现可能适用于多种以胶原酶活性过高为特征的人类疾病。